An Innovative Antibody Discovery Workflow Leveraging Machine Learning to Prioritize Leads

About the workshop
Antibody generation and validation can be time-consuming, taking up to 6-12 months using traditional screening and production methods. Even after a thorough antibody campaign, candidates often result in late-stage failure. In this webinar, explore how advancements to antibody screening methods can help you discover and develop your mAb therapies more quickly and efficiently, allowing you to generate a diverse list of antibody candidates for recombinant production with promising biophysical profiles for commercialization.
What you'll learn about
- The challenges of traditional antibody screening and production workflows
- Development of alternative technologies to increase speed, cost-effectiveness, antibody diversity, and more
- How high-throughput screening and computational approaches can generate 5-50x more antibody leads
Unable to attend live? Register today and we’ll send the recording to watch at your convenience.
About the presenter

Crystal Richardson, Ph.D.
Senior Business Partnership Manager, Azenta Life Sciences
Dr. Crystal Richardson earned her Ph.D. from the University of Virginia with a degree in biomedical sciences. She has over six years of experience in molecular biology with a focus on clinical immunology. At Azenta, Dr. Richardson supports business operations and is our subject matter expert for adeno-associated virus (AAV) and recombinant antibody production.